My research mission is to develop effective interventions to improve vaccine effectiveness, primarily by translating innovative and advanced vaccines to address equitable access and acceptability needs and, secondarily, by understanding people’s acceptability of vaccines. My research extends from basic immunology and vaccine formulation to clinical translation and vaccine acceptance and confidence. Some currently funded projects include a focus on understanding how the vaccine delivery technology impacts on the breadth of the immune response in a relevant large animal model; developing novel vaccines to tackle anti-microbial resistance and developing vaccine-based microarray patches for injection-free ease of use and ease of deployment.
VACCINE DELIVERY:
Vaccination has been fundamental in the control of infectious diseases, however effective immunization programmes are still lacking for many diseases, including emerging infectious diseases that have resulted in epidemics and pandemics. This has resulted in significant global morbidity and mortality. Inadequate deployment of vaccines has resulted in millions of children not receiving enough doses of all vaccines to fully protect them. Logistic constraints in vaccine manufacture, cold chain and the need for injection are being addressed by developing new vaccines and delivery technologies. My group aims to develop technical solutions to improve vaccine deployment A core research aim is to address vaccine logistic issues by developing thermostable, easy-to-administer, needle-free alternatives.
My group are developing a stabilising vaccine technology, based on dissolvable microneedle patches, termed ImmuPatch, The patch technology will overcome the requirement for highly trained personnel to administer the vaccine by injection, it will decrease logistic costs and increase vaccine access. Self-administration using a needle-free, patch-based system should also improve patient compliance and acceptability
The active vaccine or drug material is formulated into dissolvable microneedle (DMN) patches that are administered into the skin. Once the microneedle has inserted into the skin it dissolves, thereby delivering the drug/vaccine to the body. We developed novel processes to produce DMN which are unique and are patent protected. We defined and IP-protected new production processes and formulations that stabilise sensitive vaccines, out of cold chain, for at least 2 years .Vaccine-loaded patches induce robust immune responses in several pre-clinical models. Our formulations stabilise vaccines in solid forms, which can be used for patches or other vaccine delivery technologies. Finally, we also previously collaborated with a large EU-based drug manufacturer to develop and technology transfer a microneedle patch that delivered two of their drugs in a defined manner. This technology has been safely tested in clinical trials.
Secondly, we aim to understand how delivering vaccines by new routes, such as the skin, orally or intranasally modulates the magnitude and the type of immune response that is induced by the vaccine. We determined that administering a clinically licensed influenza vaccine into skin using ImmuPatch induced a broader neutralising antibody profile compared to intramuscular injection. We also demonstrated that administering adenovirus vectored vaccines with ImmuPatch prevents the induction of anti-vector antibody responses and, in combination with choice of dose, can induce an immune response with a better protective antibody response to blood stage malaria infection, compared to intramuscular injection. We are currently further addressing these questions in pigs.
Our current research focus includes addressing the following question: (i) how the process and formulation can be further optimised to produce physically, chemically and immunologically stable drug and vaccine-loaded DMN patches; (ii) the range of novel and licensed vaccine adjuvants that can be incorporated into microneedle patches and (iii) how and why delivery of drugs and vaccines into the skin modulates the quantity and quality of the immune response and the distribution of drug within the body. We are always interested in developing new collaborations with academic and industrial partners to further develop this technology.
VACCINE DEVELOPMENT:
In collaboration with international colleagues, we have contributed to the development of new antigens and new or repurposed adjuvants to develop new human and veterinary vaccines. For instance: We collaborated with Dame Professor Sarah Gilbert and Prof. Tess Lambe at the Jenner Institute, University of Oxford, to develop and test a T cell-inducing universal influenza virus vaccine, to protect against multiple strains of the virus that cause both seasonal and pandemic infections. We demonstrated that this strategy protects against challenge by multiple influenza virus strains. This vaccine was clinically tested by the Jenner Institute.
We are also examining the induction of mucosal immunity in pre-clinical models by vaccines containing novel adjuvants with US colleagues.
With Dutch and French colleagues, we assessed new adjuvants and new delivery routes for vaccines against porcine respiratory and reproductive virus in pigs.
VACCINE ACCEPTABILITY:
Vaccine uptake relies on the individual’s acceptance to be vaccinated and on the healthcare system’s capacity to provide access. Individual decision-making is influenced by confidence in the vaccine, lack of complacency about the seriousness of the disease and convenient access to the vaccine. The vaccine decision-making process is complex and multifaceted and multiple barriers to vaccine uptake have already been identified. However, these barriers are highly variable and context specific. One of our research aims is to identify and address barriers to optimum vaccine uptake in Ireland. This research focus is conducted in collaboration with colleagues in Clinical Pharmacy in the School of Pharmacy UCC.
We are now working on expanding this research to other vaccines, in collaboration with key healthcare and public stakeholders. We aim to develop tailored approaches to address vaccine uptake in identified contexts and to develop guidelines for future sustainable implementation of these approaches to optimise vaccine uptake.
Research funding is gratefully acknowledged from:
The European Union: OptiViVax, TRANSVAC and linked to SAPHIR SFI, Frontiers for the Future Award (FP-A-8882)SFI: SSPC The SFI Centre for Pharmaceutical ResearchHEA North-South programme. Health Research Board of Ireland (RP2007/77, POR/2012/95 and summer student scholarships)
·Enterprise Ireland (CFTD/07/117, CFTD 2011/1634 and EU Co-ordinator support)
· Science Foundation Ireland (15/BIAP/3181, 12/TIDA/I2351, National Access Programme 170, 280 and Equipment Award);
· UCC College of Medicine and Health PhD studentship and UCC Research Investment
· Industrial collaborators.
Some publicly awarded funding is listed below.
Biography
Professor Anne Moore holds a joint position between the School of Biochemistry and Cell Biology, UCC and the National Institute of Bioprocessing Research and Training (NIBRT). She completed a PhD in HIV vaccine immunology with Professor Kingston Mills and subsequently embarked upon post-doctoral work on defects in immune responses in HIV-infected individuals in the Wistar Institute in Philadelphia and further work on vaccines against viruses such as HIV and Ebola virus in Dr. Gary Nabel's lab, then at the University of Michigan. As a senior immunologist in Prof. Adrian Hill's group in the University of Oxford, she developed several vaccine candidates against malaria, TB and influenza virus. In UCC, Prof Moore moved from a lectureship in Pharmacology, based in the School of Pharmacy, UCC, to a senior lectureship in Biochemistry in 2018. She has won several awards, including leading the UCC Research Team of the Year in UCC in 2012. She undertook a sabbatical in a US vaccine biotech company, Vaxart in 2016. Here she worked on tablet-based oral vaccines for a range of therapeutic and prophylactic vaccine. Prof. Moore's research focus is to enhance vaccine accessibility and acceptability. She and her research group use both vaccine development strategies as well as qualitative research methodologies to advance these research aims. Research Interests
My research vision is to protect people against infectious diseases, equitably across the world, by increasing vaccine coverage and effectiveness. Our research is inter- and trans-disciplinary by nature.My research mission is to develop effective interventions to improve vaccine effectiveness, primarily by translating innovative and advanced vaccines to address equitable access and acceptability needs and, secondarily, by understanding people’s acceptability of vaccines. My research extends from basic immunology and vaccine formulation to clinical translation and vaccine acceptance and confidence. Some currently funded projects include a focus on understanding how the vaccine delivery technology impacts on the breadth of the immune response in a relevant large animal model; developing novel vaccines to tackle anti-microbial resistance and developing vaccine-based microarray patches for injection-free ease of use and ease of deployment.
VACCINE DELIVERY:
Vaccination has been fundamental in the control of infectious diseases, however effective immunization programmes are still lacking for many diseases, including emerging infectious diseases that have resulted in epidemics and pandemics. This has resulted in significant global morbidity and mortality. Inadequate deployment of vaccines has resulted in millions of children not receiving enough doses of all vaccines to fully protect them. Logistic constraints in vaccine manufacture, cold chain and the need for injection are being addressed by developing new vaccines and delivery technologies. My group aims to develop technical solutions to improve vaccine deployment A core research aim is to address vaccine logistic issues by developing thermostable, easy-to-administer, needle-free alternatives.
My group are developing a stabilising vaccine technology, based on dissolvable microneedle patches, termed ImmuPatch, The patch technology will overcome the requirement for highly trained personnel to administer the vaccine by injection, it will decrease logistic costs and increase vaccine access. Self-administration using a needle-free, patch-based system should also improve patient compliance and acceptability
The active vaccine or drug material is formulated into dissolvable microneedle (DMN) patches that are administered into the skin. Once the microneedle has inserted into the skin it dissolves, thereby delivering the drug/vaccine to the body. We developed novel processes to produce DMN which are unique and are patent protected. We defined and IP-protected new production processes and formulations that stabilise sensitive vaccines, out of cold chain, for at least 2 years .Vaccine-loaded patches induce robust immune responses in several pre-clinical models. Our formulations stabilise vaccines in solid forms, which can be used for patches or other vaccine delivery technologies. Finally, we also previously collaborated with a large EU-based drug manufacturer to develop and technology transfer a microneedle patch that delivered two of their drugs in a defined manner. This technology has been safely tested in clinical trials.
Secondly, we aim to understand how delivering vaccines by new routes, such as the skin, orally or intranasally modulates the magnitude and the type of immune response that is induced by the vaccine. We determined that administering a clinically licensed influenza vaccine into skin using ImmuPatch induced a broader neutralising antibody profile compared to intramuscular injection. We also demonstrated that administering adenovirus vectored vaccines with ImmuPatch prevents the induction of anti-vector antibody responses and, in combination with choice of dose, can induce an immune response with a better protective antibody response to blood stage malaria infection, compared to intramuscular injection. We are currently further addressing these questions in pigs.
Our current research focus includes addressing the following question: (i) how the process and formulation can be further optimised to produce physically, chemically and immunologically stable drug and vaccine-loaded DMN patches; (ii) the range of novel and licensed vaccine adjuvants that can be incorporated into microneedle patches and (iii) how and why delivery of drugs and vaccines into the skin modulates the quantity and quality of the immune response and the distribution of drug within the body. We are always interested in developing new collaborations with academic and industrial partners to further develop this technology.
VACCINE DEVELOPMENT:
In collaboration with international colleagues, we have contributed to the development of new antigens and new or repurposed adjuvants to develop new human and veterinary vaccines. For instance: We collaborated with Dame Professor Sarah Gilbert and Prof. Tess Lambe at the Jenner Institute, University of Oxford, to develop and test a T cell-inducing universal influenza virus vaccine, to protect against multiple strains of the virus that cause both seasonal and pandemic infections. We demonstrated that this strategy protects against challenge by multiple influenza virus strains. This vaccine was clinically tested by the Jenner Institute.
We are also examining the induction of mucosal immunity in pre-clinical models by vaccines containing novel adjuvants with US colleagues.
With Dutch and French colleagues, we assessed new adjuvants and new delivery routes for vaccines against porcine respiratory and reproductive virus in pigs.
VACCINE ACCEPTABILITY:
Vaccine uptake relies on the individual’s acceptance to be vaccinated and on the healthcare system’s capacity to provide access. Individual decision-making is influenced by confidence in the vaccine, lack of complacency about the seriousness of the disease and convenient access to the vaccine. The vaccine decision-making process is complex and multifaceted and multiple barriers to vaccine uptake have already been identified. However, these barriers are highly variable and context specific. One of our research aims is to identify and address barriers to optimum vaccine uptake in Ireland. This research focus is conducted in collaboration with colleagues in Clinical Pharmacy in the School of Pharmacy UCC.
We are now working on expanding this research to other vaccines, in collaboration with key healthcare and public stakeholders. We aim to develop tailored approaches to address vaccine uptake in identified contexts and to develop guidelines for future sustainable implementation of these approaches to optimise vaccine uptake.
Research funding is gratefully acknowledged from:
The European Union: OptiViVax, TRANSVAC and linked to SAPHIR SFI, Frontiers for the Future Award (FP-A-8882)SFI: SSPC The SFI Centre for Pharmaceutical ResearchHEA North-South programme. Health Research Board of Ireland (RP2007/77, POR/2012/95 and summer student scholarships)
·Enterprise Ireland (CFTD/07/117, CFTD 2011/1634 and EU Co-ordinator support)
· Science Foundation Ireland (15/BIAP/3181, 12/TIDA/I2351, National Access Programme 170, 280 and Equipment Award);
· UCC College of Medicine and Health PhD studentship and UCC Research Investment
· Industrial collaborators.
Some publicly awarded funding is listed below.
Research Grants
| Project | Funding Body | Start Date | End Date | Award | |
|---|---|---|---|---|---|
| Optimising a High Efficacy Plasmodium vivax Malaria Vaccine. | Horizon Europe | 01-JUN-23 | 31-MAY-28 | €451,537.00 | |
| SFI 20/FFP-A/8882 - Induction of Broad Systemic and Mucosal Immune Responses by Noninjected Stable Vaccines (X) | Science Foundation of Ireland | 01-DEC-21 | 30-NOV-25 | €1,147,643.00 | |
| AIVRT; All-island Vaccine Training Alliance. | Higher Education authority | 01-SEP-22 | 31-AUG-26 | €272,047.00 | |
| Capital Award | Enterprise Irl | 01-SEP-20 | 28-FEB-22 | €103,513.00 | |
| Let's Talk Vaccines | Irish Research Council | 01-MAY-20 | 31-DEC-21 | €5,000.00 | |
| Determinants of Vacination In Ireland: Focusing on Adolescent Vaccines | Irish Funded Research Non Exchequer | 01-APR-16 | 23-JUL-19 | €8,130.00 | |
| Development of a Microneedle-based Vaccination Technology | Industry | 18-JUL-17 | 10-DEC-19 | €35,167.00 | |
| A novel antibody approach to enhance T-cell activation for cancer therapy. | Science Foundation of Ireland | 01-JAN-16 | 31-OCT-18 | €487,251.00 | |
| Clinically relevant Viral Vector Malaria Vaccination usinng Dissolvable Microneedle Transdermal patch. | Health Research Board | 01-OCT-12 | 30-SEP-16 | €302,022.00 | |
| CoMH PhD Studentship | College of Medicine & Health | 01-OCT-12 | 30-SEP-15 | €72,000.00 | |
| Summer Scholarship | Health Research Board | 02-JUN-15 | 27-JUL-15 | €2,000.00 | |
| Development of Dissolvable Microneedle Patches for Two Licensed Drugs | Other: Not Listed | 01-JAN-12 | 31-JAN-15 | €842,309.00 | |
| Dermal Drug Delivery for Lymphatic Targeting. | Science Foundation of Ireland | 01-DEC-13 | 30-NOV-14 | €3,500.00 | |
| Stable Vacine Patches to overcome obstacles of current cold chain technologies. | Enterprise Irl | 26-JUN-13 | 25-FEB-14 | €12,500.00 | |
| Proposal preparation. | Enterprise Irl | 01-OCT-12 | 10-JUN-13 | €12,500.00 | |
| Collaborative Project ImmuPatch | Enterprise Irl | 01-MAY-12 | 31-OCT-13 | €194,042.00 | |
| Dermal Drug Delivery for Lymphatic Targeting. | Science Foundation of Ireland | 01-JAN-13 | 31-JUL-14 | €83,324.00 | |
| Pre-clinical Testing of Influenza Vaccine Incorporated in Dissolvable ImmuPatch Microneedle Arrays | European Commission | 01-NOV-11 | 30-AUG-12 | €120,000.00 | |
| EI 'Development of a Transdermal Vaccine Delivery System' - School of Pharmacy | Enterprise Irl | 01-JAN-08 | 30-APR-11 | €319,115.00 | |
| HRB 'Vaccine-Induced Protective T Cell Responses to Heterosubtypic Influenza Challenge' | Health Research Board | 01-OCT-07 | 14-JAN-11 | €286,095.00 | |
| Fabrication of Microneedle Arrays for Transdermal Vaccine Delivery with defined pore volumes and heights | Science Foundation Ireland | 01-NOV-09 | 30-MAY-10 | €25,000.00 | |
| NANOMEDIC | Enterprise Ireland | 07-SEP-09 | 06-AUG-10 | €103,746.00 | |
| HRB - Investigation of cellular infiltration induced by transdermal compared to intradermal vaccination | Health Research Board | 08-JUN-09 | 31-JUL-09 | €2,000.00 | |
| BD 17-parameter LSRII flow cytometer | Science Foundation Ireland | 01-JAN-08 | 31-DEC-08 | €340,000.00 | |
| Design and Fabrication of Microneedle Arrays for Transdermal Vaccine Delivery | Science Foundation Ireland | 01-MAY-08 | 30-JUN-08 | €25,000.00 |
Publications
Peer Reviewed Journals
| Year | Publication | |
|---|---|---|
| (2023) | 'Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs' Có-Rives I;Chen AY;Moore AC; (2023) 'Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs'. Vaccines, 11 (2) [DOI] [Details] | |
| (2023) | 'Lack of influence of social media on vaccine decision-making by university students in Ireland' Moore LE;Vucen S;Moore AC; (2023) 'Lack of influence of social media on vaccine decision-making by university students in Ireland'. Human Vaccines & Immunotherapeutics, 19 (3) [DOI] [Details] | |
| (2023) | 'Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory' Marshall S, Fleming A, Sahm LF, Moore A. (2023) 'Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory'. Vaccine, 41 (7):1368-1377 [DOI] [Details] | |
| (2023) | 'The impact of fingolimod on Treg function in brain ischaemia' Malone K;Shearer JA;Waeber C;Moore AC; (2023) 'The impact of fingolimod on Treg function in brain ischaemia'. European Journal of Immunology, [DOI] [Details] | |
| (2022) | 'Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities' Diaz, ACDC;Malone, K;Shearer, JA;Moore, AC;Waeber, C (2022) 'Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities'. Frontiers in pharmacology, 13 [DOI] [Details] | |
| (2022) | 'Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication' Moore, LE;Vucen, S;Moore, AC (2022) 'Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication'. European Journal Of Pharmaceutics And Biopharmaceutics, 173 :54-72 [DOI] [Details] | |
| (2022) | 'A Video-Based Behavioral Intervention Associated with Improved HPV Knowledge and Intention to Vaccinate' Marshall S;Moore AC;Fleming A;Sahm LJ; (2022) 'A Video-Based Behavioral Intervention Associated with Improved HPV Knowledge and Intention to Vaccinate'. Vaccines, 10 (4) [DOI] [Details] | |
| (2022) | 'Recombinant pregnancy-specific glycoprotein-1-Fc reduces functional deficit in a mouse model of permanent brain ischaemia' Malone K;Shearer JA;Williams JM;Moore AC;Moore T;Waeber C; (2022) 'Recombinant pregnancy-specific glycoprotein-1-Fc reduces functional deficit in a mouse model of permanent brain ischaemia'. Brain, Behavior, & Immunity - Health, 25 [DOI] [Details] | |
| (2021) | 'Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection' Flynn O;Dillane K;Lanza JS;Marshall JM;Jin J;Silk SE;Draper SJ;Moore AC; (2021) 'Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection'. Vaccines, 9 (3) [DOI] [Details] | |
| (2021) | 'Parent Attitudes about Childhood Vaccines: Point Prevalence Survey of Vaccine Hesitancy in an Irish Population' Marshall, S;Moore, AC;Sahm, LJ;Fleming, A (2021) 'Parent Attitudes about Childhood Vaccines: Point Prevalence Survey of Vaccine Hesitancy in an Irish Population'. Pharmacy (Basel, Switzerland), 9 [DOI] [Details] | |
| (2021) | 'Early immune responses in skin and lymph node after skin delivery of Toll-like receptor agonists in neonatal and adult pigs' Vreman S;Rebel JMJ;McCaffrey J;Ledl K;Arkhipova K;Collins D;McDaid D;Savelkoul HFJ;Skovgaard K;Moore AC;Stockhofe-Zurwieden N; (2021) 'Early immune responses in skin and lymph node after skin delivery of Toll-like receptor agonists in neonatal and adult pigs'. Vaccine, 39 (13) [DOI] [Details] | |
| (2021) | 'The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia' Malone K;Diaz Diaz AC;Shearer JA;Moore AC;Waeber C; (2021) 'The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia'. Journal of neuroinflammation, 18 (1) [DOI] [Details] | |
| (2021) | 'Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE-/- mice in the presence and absence of immunomodulation with fingolimod' Diaz Diaz AC;Malone K;Shearer JA;Moore AC;Waeber C; (2021) 'Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE-/- mice in the presence and absence of immunomodulation with fingolimod'. Data In Brief, 36 [DOI] [Details] | |
| (2020) | 'Immune responses induced by inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine in neonate pigs using different adjuvants' Sandra Vreman, Norbert Stockhofe-Zurwieden, Ditta J.Popma-de Graaf, Huub, F.J. Savelkoul, C.Barnier-Quer, N. Collin, Damien Collins, Dennis McDaid, Anne C.Moore, Johanna M.J.Rebel (2020) 'Immune responses induced by inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccine in neonate pigs using different adjuvants'. Veterinary Immunology and Immunopathology, [DOI] [Details] | |
| (2020) | 'Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection' Anne C. Moore, Emery G. Dora, Nadine Peinovich, Kiersten P. Tucker, Karen Lin, Mario Cortese, Sean N. Tucke (2020) 'Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection'. Cold Spring Harbor Symposium on Quantatitive Biology, https://doi.org/10.1101/2020.09.04.283853 [DOI] [Details] | |
| (2020) | 'A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization' Lanza J.S.;Vucen S.;Flynn O.;Donadei A.;Cojean S.;Loiseau P.M.;Fernandes A.P.S.M.;Frézard F.;Moore A.C. (2020) 'A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization'. International Journal of Pharmaceutics, 586 [DOI] [Details] | |
| (2019) | 'Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies' Donadei A.;Kraan H.;Ophorst O.;Flynn O.;O'Mahony C.;Soema P.;Moore A. (2019) 'Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies'. Journal Of Controlled Release, 311-312 :96-103 [DOI] [Details] | |
| (2019) | 'Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs' Bernelin-Cottet C.;Urien C.;McCaffrey J.;Collins D.;Donadei A.;McDaid D.;Jakob V.;Barnier-Quer C.;Collin N.;Bouguyon E.;Bordet E.;Barc C.;Boulesteix O.;Leplat J.;Blanc F.;Contreras V.;Bertho N.;Moore A.;Schwartz-Cornil I. (2019) 'Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs'. Journal Of Controlled Release, 308 :14-28 [DOI] [Details] | |
| (2019) | 'Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature' Marshall, S;Fleming, A;Moore, AC;Sahm, LJ (2019) 'Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature'. Research In Social And Administrative Pharmacy, :331-337 [DOI] [Details] | |
| (2019) | 'Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine' Vreman S.;McCaffrey J.;Popma-de Graaf D.;Nauwynck H.;Savelkoul H.;Moore A.;Rebel J.;Stockhofe-Zurwieden N. (2019) 'Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine'. Veterinary Immunology and Immunopathology, 212 :27-37 [DOI] [Details] | |
| (2019) | 'A systematic approach to map the adolescent human papillomavirus vaccine decision and identify intervention strategies to address vaccine hesitancy' Marshall S.;Sahm L.;Moore A.;Fleming A. (2019) 'A systematic approach to map the adolescent human papillomavirus vaccine decision and identify intervention strategies to address vaccine hesitancy'. Journal of Public Health, 177 :71-79 [DOI] [Details] | |
| (2019) | 'Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of ‘M2’ markers' Tremble L.;Moore A.;Forde P. (2019) 'Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of ‘M2’ markers'. Cancer Immunology Immunotherapy, [DOI] [Details] | |
| (2019) | 'Immunomodulatory Therapeutic Strategies in Stroke' Malone, K;Amu, S;Moore, AC;Waeber, C (2019) 'Immunomodulatory Therapeutic Strategies in Stroke'. Frontiers In Pharmacology, 10 [DOI] [Details] | |
| (2019) | 'The immune system and stroke: from current targets to future therapy' Malone, K;Amu, S;Moore, AC;Waeber, C (2019) 'The immune system and stroke: from current targets to future therapy'. Immunology And Cell Biology, 97 :5-16 [DOI] [Details] | |
| (2018) | 'Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats' Joyce C;Scallan CD;Mateo R;Belshe RB;Tucker SN;Moore AC; (2018) 'Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats'. Vaccine, 36 (29) [DOI] [Details] | |
| (2018) | 'The immune system and stroke: from current targets to future therapy' Malone, Kyle; Amu, Sylvie; Moore, Anne C.; Waeber, Christian (2018) 'The immune system and stroke: from current targets to future therapy'. Immunology And Cell Biology, [DOI] [Full Text] [Details] | |
| (2018) | 'Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature' Marshall S;Fleming A;Moore AC;Sahm LJ; (2018) 'Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature'. Research In Social & Administrative Pharmacy : Rsap, [DOI] [Details] | |
| (2017) | 'Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents' Marshall, Sarah; Fleming, Aoife; Moore, Anne C.; Sahm, Laura J. (2017) 'Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents'. Vaccine, 35 (37):4896-4904 [DOI] [Full Text] [Details] | |
| (2016) | 'The success of microneedle-mediated vaccine delivery into skin' Marshall, Sarah; Sahm, Laura J.; Moore, Anne C. (2016) 'The success of microneedle-mediated vaccine delivery into skin'. Human Vaccines & Immunotherapeutics, 12 (11):2975-2983 [DOI] [Full Text] [Details] | |
| (2016) | 'Dissolvable microneedle fabrication using piezoelectric dispensing technology' Allen, E. A.,O'Mahony, C.,Cronin, M.,O'Mahony, T.,Moore, A. C.,Crean, A. M. (2016) 'Dissolvable microneedle fabrication using piezoelectric dispensing technology'. International Journal of Pharmaceutics, 500 (1-2):1-10 [DOI] [Details] | |
| (2016) | 'Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use' Marshall, S;Sahm, LJ;Moore, AC (2016) 'Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use'. Vaccine, 34 :723-734 [DOI] [Details] | |
| (2016) | 'Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods' Vrdoljak, Anto; Allen, Evin A.; Ferrara, Francesca; Temperton, Nigel J.; Crean, Abina M.; Moore, Anne C. (2016) 'Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods'. Journal of controlled release : official journal of the Controlled Release Society, 225 :192-204 [DOI] [Full Text] [Details] | |
| (2016) | 'Dissolvable microneedle fabrication using piezoelectric dispensing technology' Allen, EA,O'Mahony, C,Cronin, M,O'Mahony, T,Moore, AC,Crean, AM (2016) 'Dissolvable microneedle fabrication using piezoelectric dispensing technology'. International Journal of Pharmaceutics, 500 :1-10 [DOI] [Details] | |
| (2015) | 'Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine' Pearson, Frances E.,O'Mahony, Conor,Moore, Anne C.,Hill, Adrian V. S. (2015) 'Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine'. Vaccine, 33 (28):3248-3255 [DOI] [Details] | |
| (2014) | 'Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route' Carey, JB,Vrdoljak, A,O'Mahony, C,Hill, AVS,Draper, SJ,Moore, AC (2014) 'Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route'. Scientific Reports, 4 [DOI] [Details] | |
| (2013) | 'Soluble IL-2R alpha (sCD25) enhances the development of Th17 responses and autoimmunity' Russell, S,Moore, AC,Fallon, PG,Walsh, PT (2013) 'Soluble IL-2R alpha (sCD25) enhances the development of Th17 responses and autoimmunity'. Irish Journal of Medical Science, 182 :8-8 [Details] | |
| (2013) | 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment' Goodman AL, Forbes EK, Williams AR, Douglas AD, de Cassan SC, Bauza K, Biswas S, Dicks MD, Llewellyn D, Moore AC, Janse CJ, Franke-Fayard BM, Gilbert SC, Hill AV, Pleass RJ, Draper SJ. (2013) 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment'. Scientific Reports, 3 [DOI] [Details] | |
| (2013) | 'Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1' Lambe, T,Carey, JB,Li, YY,Spencer, AJ,van Laarhoven, A,Mullarkey, CE,Vrdoljak, A,Moore, AC,Gilbert, SC (2013) 'Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1'. Scientific Reports, 3 [DOI] [Details] | |
| (2012) | 'Soluble IL-2R alpha (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice' Russell, SE,Moore, AC,Fallon, PG,Walsh, PT (2012) 'Soluble IL-2R alpha (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'. Plos One, 7 [DOI] [Details] | |
| (2012) | 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications' Galvin, P;Thompson, D;Ryan, KB;McCarthy, A;Moore, AC;Burke, CS;Dyson, M;MacCraith, BD;Gun'ko, YK;Byrne, MT;Volkov, Y;Keely, C;Keehan, E;Howe, M;Duffy, C;MacLoughlin, R (2012) 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'. Cellular and Molecular Life Sciences, 69 :389-404 [DOI] [Details] | |
| (2012) | 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines' Vrdoljak, A.,McGrath, M. G.,Carey, J. B.,Draper, S. J.,Hill, A. V.,O'Mahony, C.,Crean, A. M.,Moore, A. C. (2012) 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'. Journal of Controlled Release, 159 (11):34-4234 [Details] | |
| (2012) | 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications' Galvin P, Thompson D, Ryan K.B., McCarthy A, Moore AC, Burke CS, Dyson M, Maccraith BD, Gun'ko YK, Byrne MT, Volkov Y, Keely C, Keehan E, Howe M, Duffy C, Macloughlin R. (2012) 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'. Cellular and molecular life sciences : CMLS, 69 (3):389-404 [DOI] [Details] | |
| (2011) | 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice' Carey, John B.,Pearson, Frances E.,Vrdoljak, Anto,McGrath, Marie G.,Crean, Abina M.,Walsh, Patrick T.,Doody, Timothy,O'Mahony, Conor,Hill, Adrian V. S.,Moore, Anne C. (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. PLoS One, 6 (7) [DOI] [Details] | |
| (2011) | 'Determination of parameters for successful spray coating of silicon microneedle arrays' McGrath, MG;Vrdoljak, A;O'Mahony, C;Oliveira, JC;Moore, AC;Crean, AM (2011) 'Determination of parameters for successful spray coating of silicon microneedle arrays'. International Journal of Pharmaceutics, 415 :140-149 [DOI] [Details] | |
| (2011) | 'Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice' Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Crean, A. M.,Walsh, P. T.,Doody, T.,O'Mahony, C.,Hill, A. V.,Moore, A. C. (2011) 'Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice'. Plos One, 6 (7) [DOI] [Details] | |
| (2008) | 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei' Reyes-Sandoval, A.,Sridhar, S.,Berthoud, T.,Moore, A. C.,Harty, J. T.,Gilbert, S. C.,Gao, G.,Ertl, H. C.,Wilson, J. C.,Hill, A. V. (2008) 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'. Eur J Immunol, 38 (3):732-41 [Details] | |
| (2008) | 'Effective induction of high-titer antibodies by viral vector vaccines' Draper, S. J.,Moore, A. C.,Goodman, A. L.,Long, C. A.,Holder, A. A.,Gilbert, S. C.,Hill, F.,Hill, A. V. (2008) 'Effective induction of high-titer antibodies by viral vector vaccines'. Nat Med, 14 (8):819-21 [DOI] [Details] | |
| (2007) | 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge' Hutchings, C. L.,Birkett, A. J.,Moore, A. C.,Hill, A. V. (2007) 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'. Infect Immun, 75 (12):5819-26 [Details] | |
| (2006) | 'Safety, immunogenicity and efficacy of prime-boost immunization with recombinant pox viruses FP9 and modified vaccinia virus Ankara encoding the full length P. falciparum - circumsporozoite protein' Walther M., Thompson F., Dunachie S., Keating M., Todryk S., Berthoud T., Andrews L., Andersen R., Moore A.C., Gilbert S.C., Poulton I., Dubovsky F., Tierney E., Correa S., Huntcooke A., Butcher G., Williams J., Sinden R.E., Hill A.V.S.; (2006) 'Safety, immunogenicity and efficacy of prime-boost immunization with recombinant pox viruses FP9 and modified vaccinia virus Ankara encoding the full length P. falciparum - circumsporozoite protein'. Infection and Immunity, (74):2706-2716 [DOI] [Details] | |
| (2006) | 'Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers' Webster, D. P.,Dunachie, S.,McConkey, S.,Poulton, I.,Moore, A. C.,Walther, M.,Laidlaw, S. M.,Peto, T.,Skinner, M. A.,Gilbert, S. C.,Hill, A. V. (2006) 'Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers'. Vaccine, 24 (15):3026-34 [Details] | |
| (2005) | 'Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity' Hutchings, C. L.,Gilbert, S. C.,Hill, A. V.,Moore, A. C. (2005) 'Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity'. J Immunol, 175 (1):599-606 [Details] | |
| (2005) | 'Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance' Moore, A. C.,Gallimore, A.,Draper, S. J.,Watkins, K. R.,Gilbert, S. C.,Hill, A. V. (2005) 'Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance'. J Immunol, 175 (11):7264-73 [DOI] [Details] | |
| (2005) | 'Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: Increased durable cellular immunity with reduced immunodominance' Moore, A. C.,Gallimore, A.,Draper, S. J.,Watkins, K. R.,Gilbert, S. C.,Hill, A. V. S. (2005) 'Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: Increased durable cellular immunity with reduced immunodominance'. Journal of Immunology, 175 (11):7264-7273 [Details] | |
| (2004) | 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses' Prieur, E.,Gilbert, S. C.,Schneider, J.,Moore, A. C.,Sheu, E. G.,Goonetilleke, N.,Robson, K. J.,Hill, A. V. (2004) 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'. Proc Natl Acad Sci U S A, 101 (1):290-5 [Details] | |
| (2004) | 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells' Behboudi, S.,Moore, A.,Hill, A. V. (2004) 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'. Cell Immunol, 228 (1):15-9 [Details] | |
| (2004) | 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria' Moore, A. C.,Hill, A. V. (2004) 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'. Immunol Rev, 199 :126-43 [Details] | |
| (2003) | 'A Plasmodium falciparum candidate vaccine based on a six antigen polyprotein encoded by recombinant poxviruses' Prieur, E.,Gilbert, S.,Schneider, J.,Moore, A. C.,Sheu, E.,Goonetilleke, N.,Robson, K. J.,Hill, A. (2003) 'A Plasmodium falciparum candidate vaccine based on a six antigen polyprotein encoded by recombinant poxviruses'. Proc Natl Acad Sci U S A, [Details] | |
| (2002) | 'Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma' Liyanage, U. K.,Moore, T. T.,Joo, H. G.,Tanaka, Y.,Herrmann, V.,Doherty, G.,Drebin, J. A.,Strasberg, S. M.,Eberlein, T. J.,Goedegebuure, P. S.,Linehan, D. C. (2002) 'Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma'. J Immunol, 169 (5):2756-61 [Details] | |
| (1999) | 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1' Moore A, McCarthy L, Mills KH; (1999) 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'. Vaccine, 17 (20-21):2517-2527 [Details] | |
| (1999) | 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1' Moore, A.,McCarthy, L.,Mills, K. H. (1999) 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'. Vaccine, 17 (20-21):2517-27 [Details] | |
| (1997) | 'Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group' Nashan, B.,Moore, R.,Amlot, P.,Schmidt, A. G.,Abeywickrama, K.,Soulillou, J. P. (1997) 'Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group'. Lancet, 350 (9086):1193-8 [Details] | |
| (1995) | 'Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2' Gooding, R.,Riches, P.,Dadian, G.,Moore, J.,Gore, M. (1995) 'Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2'. Br J Cancer, 72 (2):452-5 [Details] | |
| (1995) | 'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells' Moore A, McGuirk P, Adams S, Jones WC, McGee JP, O'Hagan DT, Mills KH.; (1995) 'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells'. Vaccine, 13 (18):1741-1749 [Details] | |
| (2016) | 'Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use' Marshall, Sarah; Sahm, Laura J.; Moore, Anne C. (2016) 'Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use'. Vaccine, 34 (6):723-34 [DOI] [Full Text] [Details] | |
| (2015) | 'Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine' Pearson, F. E.,O'Mahony, C.,Moore, A. C.,Hill, A. V. (2015) 'Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine'. Vaccine, 33 (28):3248-55 [DOI] [Details] | |
| (2014) | 'Production of dissolvable microneedles using an atomised spray process: effect of microneedle composition on skin penetration' McGrath, M. G.,Vucen, S.,Vrdoljak, A.,Kelly, A.,O'Mahony, C.,Crean, A. M.,Moore, A. (2014) 'Production of dissolvable microneedles using an atomised spray process: effect of microneedle composition on skin penetration'. Eur J Pharm Biopharm, 86 (2):200-11 [DOI] [Details] | |
| (2014) | 'Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles' Paleco R., Vučen S.R., Crean A.M., Moore A.C., Scalia S (2014) 'Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles'. International Journal of Pharmaceutics, [DOI] [Details] | |
| (2014) | 'Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route' Carey, John B.,Vrdoljak, Anto,O'Mahony, Conor,Hill, Adrian V. S.,Draper, Simon J.,Moore, Anne C. (2014) 'Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route'. Scientific Reports, 4 [DOI] [Details] | |
| (2013) | 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment' Goodman, Anna L.,Forbes, Emily K.,Williams, Andrew R.,Douglas, Alexander D.,de Cassan, Simone C.,Bauza, Karolis,Biswas, Sumi,Dicks, Matthew D. J.,Llewellyn, David,Moore, Anne C.,Janse, Chris J.,Franke-Fayard, Blandine M.,Gilbert, Sarah C.,Hill, Adrian V. S.,Pleass, Richard J.,Draper, Simon J. (2013) 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment'. Scientific Reports, 3 [DOI] [Details] | |
| (2013) | 'Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1' Lambe, T.,Carey, J. B.,Li, Y.,Spencer, A. J.,van Laarhoven, A.,Mullarkey, C. E.,Vrdoljak, A.,Moore, A. C.,Gilbert, S. C. (2013) 'Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1'. Sci Rep, 3 [DOI] [Details] | |
| (2013) | 'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles' Vucen, SR;Vuleta, G;Crean, AM;Moore, AC;Ignjatovic, N;Uskokovic, D (2013) 'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'. Journal of Pharmacy and Pharmacology, 65 :1451-1462 [DOI] [Details] | |
| (2013) | 'Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration' McGrath MG, Vucen S, Vrdoljak A, Kelly A, O'Mahony C, Crean AM, Moore AC. (2013) 'Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration'. European Journal of Pharmaceutical Science, Epub ahead of print [DOI] [Details] | |
| (2012) | 'Soluble IL-2Ralpha (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice' Russell, S. E.,Moore, A. C.,Fallon, P. G.,Walsh, P. T. (2012) 'Soluble IL-2Ralpha (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice'. PLoS One, 7 (10) [DOI] [Details] | |
| (2012) | 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines' Vrdoljak, Anto,McGrath, Marie G.,Carey, John B.,Draper, Simon J.,Hill, Adrian V. S.,O'Mahony, Conor,Crean, Abina M.,Moore, Anne C. (2012) 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'. Journal of Controlled Release, 159 (1):34-42 [DOI] [Details] | |
| (2012) | 'Method for fabricating a microneedle, and produced microneedle' Moore, A.,Vrdoljak, A. (2012) 'Method for fabricating a microneedle, and produced microneedle'. WO2012153266 A3, [Details] | |
| (2012) | 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications' Galvin, Paul,Thompson, Damien,Ryan, Katie B.,McCarthy, Anna,Moore, Anne C.,Burke, Conor S.,Dyson, Maya,MacCraith, Brian D.,Gun'ko, Yurii K.,Byrne, Michelle T.,Volkov, Yuri,Keely, Chris,Keehan, Enda,Howe, Michael,Duffy, Conor,MacLoughlin, Ronan (2012) 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'. Cellular and Molecular Life Sciences, 69 (3):389-404 [DOI] [Details] | |
| (2011) | 'Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria (vol 5, pg 95, 2009)' Draper, Simon J.,Goodman, Anna L.,Biswas, Sumi,Forbes, Emily K.,Moore, Anne C.,Gilbert, Sarah C.,Hill, Adrian V. S. (2011) 'Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria (vol 5, pg 95, 2009)'. Cell Host & Microbe, 9 (3):252-252 [DOI] [Details] | |
| (2011) | 'Microneedle Array Design Determines the Induction of Protective Memory CD8+ T cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice' Carey, J. B.,Pearson, F.E.,Vrdoljak, A.,McGrath, M. G.,Crean, A.,Walsh, P.T.,Doody, T.,O'Mahony, C.,Hill, A.V.,Moore, A.C. (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8+ T cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. PLoS One, 6 (7) [DOI] [Details] | |
| (2011) | 'Determination of parameters for successful spray coating of silicon microneedle arrays' McGrath MG, Vrdoljak A, O'Mahony C, Oliveira JC, Moore AC, Crean AM; (2011) 'Determination of parameters for successful spray coating of silicon microneedle arrays'. International Journal of Pharmaceutics, 415 :140-149 [DOI] [Full Text] [Details] | |
| (2011) | 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice' Carey, JB,Pearson, FE,Vrdoljak, A,McGrath, MG,Crean, AM,Walsh, PT,Doody, T,O'Mahony, C,Hill, AVS,Moore, AC; (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. Plos One, 6 [DOI] [Details] | |
| (2011) | 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei (vol 38, pg 732, 2008)' Reyes-Sandoval, Arturo,Sridhar, Saranya,Berthoud, Tamara,Moore, Anne C.,Harty, John T.,Gilbert, Sarah C.,Gao, Guangping,Ertl, Hildegund C. J.,Wilson, James C.,Hill, Adrian V. S. (2011) 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei (vol 38, pg 732, 2008)'. European Journal of Immunology, 41 (5):1501-1501 [DOI] [Details] | |
| (2010) | 'Development of stabilized vaccines with needle-free devices for targeted skin immunization' Moore, A. C., Crean, A. M., O¿Mahony; (2010) 'Development of stabilized vaccines with needle-free devices for targeted skin immunization'. European Pharmaceutical Review, 15 (6):56-60 [Full Text] [Details] | |
| (2010) | 'Development of stabilized vaccines with needle-free devices for targeted skin immunization' Crean, A.,O'Mahony, C.,Moore, A.C. (2010) 'Development of stabilized vaccines with needle-free devices for targeted skin immunization'. European Pharmaceutical Review, 15 (6):56-60 [Details] | |
| (2010) | 'Proof of concept study to investigate the efficacy of microneedle arrays in local anaesthetic administration to human skin' McAleer, M.A.,Moore, A. C.,Crean, A.,O'Mahony, C.,Bourke, J. F. (2010) 'Proof of concept study to investigate the efficacy of microneedle arrays in local anaesthetic administration to human skin'. Br J Dermatol, 163 (Suppl 1) [Details] | |
| (2009) | 'Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria' Draper, Simon J.,Goodman, Anna L.,Biswas, Sumi,Forbes, Emily K.,Moore, Anne C.,Gilbert, Sarah C.,Hill, Adrian V. S. (2009) 'Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria'. Cell Host & Microbe, 5 (1):95-105 [DOI] [Details] | |
| (2008) | 'Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A' Sridhar, S.,Reyes-Sandoval, A.,Draper, S. J.,Moore, A. C.,Gilbert, S. C.,Gao, G. P.,Wilson, J. M.,Hill, A. V. (2008) 'Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A'. J Virol, 82 (8):3822-33 [DOI] [Details] | |
| (2008) | 'Effective induction of high-titer antibodies by viral vector vaccines' Draper, Simon J.,Moore, Anne C.,Goodman, Anna L.,Long, Carole A.,Holder, Anthony A.,Gilbert, Sarah C.,Hill, Fergal,Hill, Adrian V. S. (2008) 'Effective induction of high-titer antibodies by viral vector vaccines'. Nature Medicine, 14 (8):819-821 [DOI] [Details] | |
| (2008) | 'New vectored vaccines for malaria' Hill, Adrian V. S.,Reyes-Sandoval, Arturo,Draper, Simon,O'Hara, Geraldine,Spencer, Alex,Cottingham, Matt,Sridhar, Saranya,Moore, Anne,Goodman, Anna,Larsen, Karen,Saurya, Saroj,Calvert, Alice,Furze, Julie,Biswas, Sumi,Forbes, Emily,Berrie, Eleanor,Bird, Pru,Bregu, Migena,Rollier, Christine,Lawrie, Alison,Rowland, Res,Ertl, Hildegund,Nicosia, Alfredo,Siani, Loredana,Colloca, Stefano,Cortese, Riccardo,Wyllie, David,Gilbert, Sarah C. (2008) 'New vectored vaccines for malaria'. International Journal for Parasitology, 38 [Details] | |
| (2008) | 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei' Reyes-Sandoval, Arturo,Sridhar, Saranya,Berthoud, Tamara,Moore, Anne C.,Harty, John T.,Gilbert, Sarah C.,Gao, Guangping,Ertl, Hildegund C. J.,Wilson, James C.,Hill, Adrian V. S. (2008) 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'. European Journal of Immunology, 38 (3):732-741 [DOI] [Details] | |
| (2008) | 'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria' Schmidt, Nathan W.,Podyminogin, Rebecca L.,Butler, Noah S.,Badovinac, Vladimir P.,Tucker, Brad J.,Bahiat, Keith S.,Lauer, Peter,Reyes-Sandoval, Arturo,Hutchings, Claire L.,Moore, Anne C.,Gilbert, Sarah C.,Hill, Adrian V.,Bartholomay, Lyric C.,Harty, John T. (2008) 'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria'. Proceedings of the National Academy of Sciences of the United States of America, 105 (37):14017-14022 [DOI] [Details] | |
| (2008) | 'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria' Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, Gilbert SC, Hill AV, Bartholomay LC, Harty JT.; (2008) 'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria'. Proceedings of The National Academy of Sciences of The United States of America, 105 (37):14017-14022 [DOI] [Details] | |
| (2008) | 'Single dose protection against P. berghei by Simian Adenoviral vector using human CMV promoter containing Intron A' Sridhar S., Reyes-Sandoval A., Draper S.J., Moore A.C., Gilbert S.C., Gao G.P., Wilson J.M. and Hill A.V.S. ; (2008) 'Single dose protection against P. berghei by Simian Adenoviral vector using human CMV promoter containing Intron A'. Journal of Virology, (82):3822-3833 [Details] | |
| (2008) | 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei' Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., Gao G.P., Ertl H.C., Wilson J.M. and Hill A.V.S. ; (2008) 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'. European Journal of Immunology, (38):732-741 [DOI] [Details] | |
| (2007) | 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge' Hutchings C.L, Birkett A.J., Moore A.C., and Hill A.V.S. ; (2007) 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'. Infection and Immunity, (95):5819-5826 [DOI] [Details] | |
| (2007) | 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge' Hutchings, Claire L.,Birkett, Ashley J.,Moore, Anne C.,Hill, Adrian V. S. (2007) 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'. Infection and Immunity, 75 (12):5819-5826 [DOI] [Details] | |
| (2008) | 'Multi-Stage Protection against Malaria using Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1' Draper S.J, Moore A.C., Goodman A.L., Long C.A., Holder A.A., Gilbert S.C., Hill F., Hill A.V.S.; (2008) 'Multi-Stage Protection against Malaria using Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1'. Nature medicine, (14):819-821 [DOI] [Details] | |
| (2007) | 'Combination Vaccines; synergistic simultaneous induction of antibody and T cell immunity results in enhanced vaccine efficacy' Moore A.C. Hutchings C.L.; (2007) 'Combination Vaccines; synergistic simultaneous induction of antibody and T cell immunity results in enhanced vaccine efficacy'. Expert Review of Vaccines, 6 (1):111-121 [DOI] [Details] | |
| (2007) | 'Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity' Moore, A. C.,Hutchings, C. L. (2007) 'Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity'. Expert Rev Vaccines, 6 (1):111-21 [Details] | |
| (2006) | 'Safety of Recombinant Fowlpox Strain 9 and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage P. falciparum Malaria in Non-Immune Volunteers' Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., Laidlaw S.M., Peto T., Skinner M.A., Gilbert S. C., Hill A.V.S.; (2006) 'Safety of Recombinant Fowlpox Strain 9 and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage P. falciparum Malaria in Non-Immune Volunteers'. Vaccine, (24):3026-3034 [DOI] [Details] | |
| (2006) | 'Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein' Walther, M.,Thompson, F. M.,Dunachie, S.,Keating, S.,Todryk, S.,Berthoud, T.,Andrews, L.,Andersen, R. F.,Moore, A.,Gilbert, S. C.,Poulton, I.,Dubovsky, F.,Tierney, E.,Correa, S.,Huntcooke, A.,Butcher, G.,Williams, J.,Sinden, R. E.,Hill, A. V. S. (2006) 'Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein'. Infection and Immunity, 74 (5):2706-2716 [DOI] [Details] | |
| (2005) | 'Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity' Hutchings, C. L.,Gilbert, S. C.,Hill, A. V. S.,Moore, A. C. (2005) 'Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity'. Journal of Immunology, 175 (1):599-606 [Details] | |
| (2005) | 'Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance' Moore A.C., Gallimore A., Draper S., Watkins K.R., Gilbert S.C. and Hill A.V.S. ; (2005) 'Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance'. Journal of Immunology, (175):7264-7273 [Details] | |
| (2004) | 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria' Moore, A. C.,Hill, A. V. S. (2004) 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'. Immunological Reviews, 199 (1):126-143 [DOI] [Details] | |
| (2004) | 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses' Prieur E, Gilbert S.C., Schneider J ., Moore A.C. , Sheu E.G, Goonetilleke N., Robson K.J.H., and Hill A.V. ; (2004) 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'. Proceedings of The National Academy of Sciences of The United States of America, (101):290-295 [DOI] [Details] | |
| (2004) | 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction' Behboudi, S.,Moore, A.,Gilbert, S. C.,Nicoll, C. L.,Hill, A. V. (2004) 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'. Vaccine, 22 (31-32):4326-31 [Details] | |
| (2004) | 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells' Behboudi, S.,Moore, A.,Hill, A. V. S. (2004) 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'. Cellular Immunology, 228 (1):15-19 [DOI] [Details] | |
| (2002) | 'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice' Moore, A. C.,Kong, W. P.,Chakrabarti, B. K.,Nabel, G. J. (2002) 'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice'. J Virol, 76 (1):243-50 [Details] | |
| (2005) | 'Novel Protein and Poxvirus Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell Mediated Immunity' Hutchings C.L, Gilbert S.C., Hill A.V.S and Moore A.C.; (2005) 'Novel Protein and Poxvirus Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell Mediated Immunity'. Journal of Immunology, (175):599-606 [Details] | |
| (2004) | 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria' Moore AC, Hill AV; (2004) 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'. Immunological reviews, 199 :126-143 [DOI] [Details] | |
| (2004) | 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction' Behboudi, S.,Moore, A.,Gilbert, S. C.,Nicoll, C. L.,Hill, A. V. S. (2004) 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'. Vaccine, 22 (31-32):4326-4331 [DOI] [Details] | |
| (2004) | 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells' Behboudi S., Moore A.C. and Hill A.V.S. ; (2004) 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'. Cellular Immunology, (228):15-19 [DOI] [Details] | |
| (2004) | 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction' Behboudi S., Moore A.C., Gilbert S., Nicoll C.L. and Hill A.V.S. ; (2004) 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'. Vaccine, 22 :4326-4331 [DOI] [Details] | |
| (2004) | 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses' Prieur, E.,Gilbert, S. C.,Schneider, J.,Moore, A. C.,Sheu, E. G.,Goonetilleke, N.,Robson, K. J. H.,Hill, A. V. S. (2004) 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'. Proceedings of the National Academy of Sciences of the United States of America, 101 (1):290-295 [DOI] [Details] | |
| (2002) | 'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice' Moore AC, Kong WP, Chakrabarti BK, Nabel GJ; (2002) 'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice'. Journal of virology, 76 (1):243-250 [DOI] [Details] | |
| (2000) | 'Inhibition of Interleukin-12 production in human monocyte-derived macrophages by Tumor Necrosis Factor' Ma X., Sun J., Papasavvas E., Riemann H., Robertson S., Marshall J., Bailer R.T., Moore A.C., Donnelly R., Trinchieri G., Montaner L.J.,; (2000) 'Inhibition of Interleukin-12 production in human monocyte-derived macrophages by Tumor Necrosis Factor'. Journal of Immunology, 164 :1722-1729 [Details] | |
| (2000) | 'Inhibition of IL-12 production in human monocyte-derived macrophages by TNF' Ma, X.,Sun, J.,Papasavvas, E.,Riemann, H.,Robertson, S.,Marshall, J.,Bailer, R. T.,Moore, A.,Donnelly, R. P.,Trinchieri, G.,Montaner, L. J. (2000) 'Inhibition of IL-12 production in human monocyte-derived macrophages by TNF'. J Immunol, 164 (4):1722-9 [Details] | |
| (1999) | 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1' Moore, A.,McCarthy, L.,Mills, K. H. G. (1999) 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'. Vaccine, 17 (20-21):2517-2527 [DOI] [Details] | |
| (1998) | 'Approaches to new vaccines' Mahon BP, Moore A, Johnson PA, Mills KH.; (1998) 'Approaches to new vaccines'. Critical Review of Biotechnology, 18 (4):257-282 [Details] | |
| (1995) | 'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells' Moore, A.,McGuirk, P.,Adams, S.,Jones, W. C.,McGee, J. P.,O'Hagan, D. T.,Mills, K. H. (1995) 'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells'. Vaccine, 13 (18):1741-9 [Details] | |
| (1995) | 'An adjuvant formulation that switches Th2 to Th1 responses with soluble recombinant HIV proteins' Moore A, Adams S., Garcon N., Delchambre M., Thriart C., Bruck C. and Mills KH.; (1995) 'An adjuvant formulation that switches Th2 to Th1 responses with soluble recombinant HIV proteins'. Immunology, 86 [Details] | |
| (1994) | 'Factors affecting Th1 and Th2 cell induction and immunoglobulin class switching in the immune response to HIV proteins' Moore A.C., Adams S., and Mills K.H.G.; (1994) 'Factors affecting Th1 and Th2 cell induction and immunoglobulin class switching in the immune response to HIV proteins'. Immunology, 83, S1 [Details] |
Other Journals
| Year | Publication | |
|---|---|---|
| (2010) | 'Development of Stabilised Vaccines with Needle-Free Devices for Targeted Skin Immunization' A. Crean, C. O’Mahony and A. C. Moore (2010) 'Development of Stabilised Vaccines with Needle-Free Devices for Targeted Skin Immunization' European Pharmaceutical Review, 15 (6) :56-60. [Details] |
Conference Publications
| Year | Publication | |
|---|---|---|
| (2013) | 35th All-Ireland Schools of Pharmacy Conference Allen, E.,Crean, A.,O’Mahony, C.,Moore, A. C. (2013) Influenza Vaccination using Dissolvable ImmuPatchInfluenza Vaccination using Dissolvable ImmuPatch 35th All-Ireland Schools of Pharmacy Conference Belfast, UK, [Details] | |
| (2012) | 2nd International Conference on Microneedles: Microneedles 2012 A. M. Crean, M. G. McGrath, C. O’Mahony, A. Vrdoljak and A. C. Moore (2012) Dissolvable ImmuPatch Microneedles for Drug Delivery 2nd International Conference on Microneedles: Microneedles 2012 Cork, , 13-MAY-12 - 15-MAY-12 [Details] | |
| (2011) | 38th Annual Meeting and Exposition of the Controlled Release Society McGrath, M. G.,O'Mahony, C.,Vrdoljak, A.,Moore, A. C.,Crean, A. (2011) Design of Dissolvable Microneedles for Drug DeliveryDesign of Dissolvable Microneedles for Drug Delivery 38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USA, [Details] | |
| (2011) | 38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,Crean, A.,O'Mahony, C.,Hill, A. V. S.,Moore, A. C. (2011) Immunization using ImmuPatch silicon microneedles results in enhanced T-cell and antibody responses compare to traditional imunization routesImmunization using ImmuPatch silicon microneedles results in enhanced T-cell and antibody responses compare to traditional imunization routes 38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USAMaryland, USA, [Details] | |
| (2011) | Skin Vaccination Summit 2011 Moore, A. C.,Pearson, F.,Vrdoljak, A.,McGrath, M. G.,Draper, S.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2011) ces for vaccination Skin Vaccination Summit 2011 Washington, USA, , 11-OCT-11 [Details] | |
| (2011) | Skin Vaccination Summit 2011Skin Vaccination Summit 2011 O'Mahony, C.,Moore, A. C.,Blake, A.,Scully, J.,O'Brien, J.,Hegarty, M. (2011) Silicon microneedles for vaccine deliverySilicon microneedles for vaccine delivery Skin Vaccination Summit 2011Skin Vaccination Summit 2011 Washington, USAWashington, USA, [Details] | |
| (2011) | 38th Annual Meeting and Exposition of the Controlled Release Society Vrdoljak, A.,McGrath, M. G.,Crean, A.,O'Mahony, C.,Moore, A. C. (2011) Development of ImmuPatch arrays coated with live vaccine 38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USA, [Details] | |
| (2011) | 38th Annual Meeting Controlled Release Society John B. Carey, Frances E. Pearson, Anto Vrdoljak, Abina M. Crean, Conor O¿Mahony, Adrian V.S. Hill, Anne C. Moore; (2011) Immunization using ImmuPatch Silicon Microneedle Arrays results in Enhanced T 38th Annual Meeting Controlled Release Society National Harbor, Maryland, U.S.A, [Details] | |
| (2011) | 38th Annual Meeting Controlled Release Society M.G. McGrath, C.O¿Mahony, A. Vrdoljak, A.C. Moore, A.M. Crean; (2011) Design of Dissolvable Microneedles for Drug Delivery 38th Annual Meeting Controlled Release Society National Harbor, Maryland, U.S.A, [Details] | |
| (2010) | 12th International Conference on Perspectives in Percutaneous Penetration M. G. McGrath, C. O¿Mahony, J. B. Carey, A. Vrdoljak, A. C. Moore and A. M. Crean; (2010) Spray Coating of Silicon Microneedle Patches for Intradermal Drug Delivery 12th International Conference on Perspectives in Percutaneous Penetration [Details] | |
| (2010) | Perspectives in Percutaneous Penetreation McGrath M., O¿Mahony C., Carey J.B., Vrdoljak A., Moore A.C. and Crean A; (2010) Spray Coating of Silicon Microneedle Patches for Intradermal Drug Delivery Perspectives in Percutaneous Penetreation La Grande Motte, France, , 06-APR-10 - 08-APR-10 [Details] | |
| (2010) | Modern Mucosal Vaccines and Adjuvants Moore A.C., Carey J.B, Pearson F.E., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C. ; (2010) Enhanced T cell and Antibody Responses induced by ImmuPatch Transdermal Vaccination Modern Mucosal Vaccines and Adjuvants Dublin, Ireland, , 28-APR-10 - 30-APR-10 [Details] | |
| (2010) | Microneedles 2010Microneedles 2010 Pearson, F. E.,Reyes-Sandoval, A.,O'Mahony, C.,Moore, A. C.,Hill, A. V. S. (2010) Delivery of Recombinant Adenoviral Vector malaria vaccines by ImmuPatch Induces Protective CD8+ T-cell Mediated Immunity Against Parasite ChallengeDelivery of Recombinant Adenoviral Vector malaria vaccines by ImmuPatch Induces Protective CD8+ T-cell Mediated Immunity Against Parasite Challenge Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details] | |
| (2010) | Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010) O'Mahony, C.,Blake, A.,Scully, J.,O'Brien, J.,Moore, A. C. (2010) Silicon Microneedles for Painless Percutaneous PenetrationSilicon Microneedles for Painless Percutaneous Penetration Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010) La Grande Motte, FranceLa Grande Motte, France, [Details] | |
| (2010) | Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 O'Mahony, C.,Blake, A.,Scully, J.,O'Brien, J.,Moore, A. C. (2010) Silicon Microneedles for Painless Percutaneous PenetrationSilicon Microneedles for Painless Percutaneous Penetration Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Cork, IrelandCork, Ireland, [Details] | |
| (2010) | MMVAM 2010 Moore, A. C.,Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Draper, S. J.,Gilbert, S. C.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2010) Enhanced T-cell and Antibody Responses Induced by ImmuPatch Transdermal Vaccination MMVAM 2010 Dublin, IrelandDublin, Ireland, [Details] | |
| (2010) | Microneedles 2010Microneedles 2010 Moore, A. C.,Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Draper, S. J.,Gilbert, S. C.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2010) Enhanced Immune Responses Induced by ImmuPatch Transcutaneous VaccinationEnhanced Immune Responses Induced by ImmuPatch Transcutaneous Vaccination Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details] | |
| (2010) | 4th Vaccine and ISV Annual Global Congress4th Vaccine and ISV Annual Global Congress Moore, A. C.,Carey, J. B.,Crean, A.,Vrdoljak, A.,McGrath, M. G.,O'Mahony, C. (2010) Percutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T-cell and antibody responses compared to traditional immunization routes 4th Vaccine and ISV Annual Global Congress4th Vaccine and ISV Annual Global Congress Vienna, Austria, [Details] | |
| (2010) | Microneedles 2010Microneedles 2010 McGrath, M. G.,Vrdoljak, A.,O'Mahony, C.,Carey, J. B.,Moore, A. C.,Crean, A. (2010) Percutaneous vaccine Delivery Using MicroneedlesPercutaneous vaccine Delivery Using Microneedles Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details] | |
| (2010) | Perspectives in Percutaneous Penetreation Moore A.C., Carey J.B., McGrath M. Pearson F.E., Vrdoljak A. Hill A.V.S., Crean A. and O¿Mahony C. ; (2010) Percutaneous immununization using ImmuPatch: Comparison of vaccine localisation and induction of antibody and T cell responses in a pre-clinical model Perspectives in Percutaneous Penetreation La Grande Motte, France, , 06-APR-10 - 10-APR-10 [Details] | |
| (2010) | Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Carey, J. B.,Moore, A. C.,McGrath, M. G.,Pearson, F.,Hill, A. V. S.,Moore, A. C. (2010) Percutaneous Immunization using Immupatch; Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical ModelPercutaneous Immunization using Immupatch; Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical Model Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Cork, IrelandCork, Ireland, [Details] | |
| (2010) | Perspectives in Percutaneous Penetration (PPP 2010) McGrath, M. G.,O'Mahony, C.,Carey, J. B.,Vrdoljak, A.,Moore, A. C.,Crean, A. (2010) Percutaneous Immunization Using ImmuPatch: Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical Model Perspectives in Percutaneous Penetration (PPP 2010) La Grande Motte, France, [Details] | |
| (2010) | First International Conference on Microneedles Moore A.C., Carey J.B., Pearson F., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C., ; (2010) Enhanced Immune Responses induced by ImmuPatch Transcutaneous Vaccination First International Conference on Microneedles Atlanta, Georgia, , 24-MAY-10 - 26-MAY-10 [Details] | |
| (2010) | First International Conference on Microneedles McGrath M., Vrdoljak A., O¿Mahony C., Carey J.B., Moore A.C. and Crean A.; (2010) Percutaneous Vaccine Delivery Using Microneedles First International Conference on Microneedles Atlanta, Georgia, , 24-MAY-10 - 26-APR-10 [Details] | |
| (2010) | 4th Vaccine and ISV Annual Global Congress A.C. Moore, J. Carey, F. Pearson, A. Vrdoljak, M. McGrath, S. Draper, S. Gilbert, A. Hill, A. Crean and C. O¿Mahony; (2010) Percutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T cell and antibody responses compared to traditional immunization routes 4th Vaccine and ISV Annual Global Congress Vienna, Austria, , 03-OCT-10 - 05-OCT-10 [Details] |
Published Reports
| Year | Publication | |
|---|---|---|
| (2006) | The use of non-human primates in research, chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society. Sir David Weatherall; (2006) The use of non-human primates in research, chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society. Wellcome Trust, MRC, The Royal Society, UK. [Details] |
Professional Activities
Honours and Awards
| Year | Title | Awarding Body | |
|---|---|---|---|
| 2013 | Joint Winner "Get Started Technology Venture Programme" | SFI | |
| 2012 | UCC Research Team of the Year | UCC |
Patents
| Patent Number | Title | Granted | |
|---|---|---|---|
| WO2004110482 | Combination Vaccines | 26-OCT-06 | |
| WO2005115451 | METHODS FOR GENERATING IMPROVED IMMUNE RESPONSE | 08-DEC-05 | |
| UK1007204.9 | Microneedle Array | 29-APR-10 | |
| UK 1007207.2 | Microneedle kits for vaccine delivery | 29-APR-10 | |
| GB1107642.9 | Method for making dissolvable microneedle patches | 09-MAY-11 | |
| GB1019577.4 | Method to prepare dissolvable microneedles. | 18-NOV-10 |
Disclosures
| Title | Inventor | Submitted | |
|---|---|---|---|
| Composition of microneedle patch for dermal drug delivery and method of production. | Moore, A.C., Vucen, S, O’Sullivan, C, Crean, A.M | 16-DEC-14 | |
| T cell inducing influenza virus vaccines. | Gilbert S.C., Moore A.C., and Hill A.V.S | 28-SEP-07 | |
| Method of fabrication and composition of dissolvable microneedles. | Crean A, McGrath M., Vrdoljak A, O¿Mahony C. and Moore A.C Submitted April 2010 | 21-APR-10 | |
| Method of fabrication and composition of dissolvable microneedle patches | Vrdoljak A, Crean A, McGrath M., O¿Mahony C. and Moore A.C | 21-APR-10 | |
| Methods of modulating cell surface expression of the IL-2 receptor | Dev K.K., Moore A.C | 24-JUN-08 |
Committees
| Committee | Function | From / To | |
|---|---|---|---|
| Royal Irish Academy Life and Health Sciences Committee | Member | 2022 / | |
| National COVID-19 Advisory Group | Member | 2022 / | |
| Equality, Diversity and Inclusion | Chair | 2021 / 2024 | |
| School of Biochemistry Athena SWAN Self Assessment Team | Chair | 2019 / 1921 | |
| College Athena SWAN Committee | School Representative, Member | 2019 / 2024 | |
| School of Pharmacy Athena Swan Working Group | Member | 2017 / | |
| School Research Committee | Member | 2018 / 2024 | |
| University Animal Welfare Body | Member | 2019 / 2024 | |
| University BSU Policy Committee | Represent CoMH | 2015 / 2018 | |
| Organising Comittee for International Microneedle Conference | Committee member | 2010 / 2017 | |
| School of Pharmacy, Research and Graduate Studies Committee | Chair | 2008 / 2014 | |
| School of Pharmacy, Research Quality Review Committee | Vice-Chair | 2008 / 2009 | |
| School of Pharmacy, Quality Review Committee | Vice-Chair | 2008 / 2009 | |
| College of Medicine and Health Research Committee | Member | 2009 / | |
| University Genetically Modified Biological Organisms Committee. | Member | 2009 / 2017 | |
| College of Medicine and Health Graduate School Committee | Member | 2010 / 2014 |
Conference Contributions
| Year | Publication | |
|---|---|---|
| (2017) | 12th Annual Cochrane Conference, Marshall S, Fleming A, Moore AC, Sahm LJ (2017) Systematic Review and meta-ethnographic synthesis protocol: opinions on HPV vaccination. [Invited Lectures (Conference)], 12th Annual Cochrane Conference, NUI Galway . [Details] | |
| (2017) | Health Services Research and Pharmacy Practice Conference,, Marshall S, Fleming A, Moore AC, Sahm LJ. (2017) Acceptability of microneedle patch vaccines: a qualitative study into the opinions of Irish parents. [Poster Presentation], Health Services Research and Pharmacy Practice Conference,, University of Nottingham, UK . [Details] | |
| (2017) | Skin Vaccination Summit, Agnese Donadei, Olga Resink, Ivo Ploemen, Olivia Flynn, Anne Moore (2017) Development of Dissolvable Microneedle Patches for Dermal Delivery of Polio Vaccines. [Poster Presentation], Skin Vaccination Summit, Leiden . [Details] | |
| (2017) | Modern Vaccines Adjuvants and Delivery Systems, Agnese Donadei, Olga Ophorst, Rimko Ten Have, Heleen Kraan, Olivia Flynn, Ivo Ploemen, Anne Moore (2017) Effective Dermal Polio Vaccination through Dissolvable Microneedle Patches. [Poster Presentation], Modern Vaccines Adjuvants and Delivery Systems, Porto, Portugal . [Details] | |
| (2017) | Skin Vaccine Summit,, A Moore (2017) Adenovirus and Subunit Vaccine Stabilization and Immunogenicity in Small and Large Animals”. [Invited Lectures (Conference)], Skin Vaccine Summit,, Leiden . [Details] | |
| (2017) | All-Ireland Schools of Pharmacy Conference, Marshall S, Fleming A, Moore AC, Sahm LJ. (2017) Acceptability of microneedle-patch vaccines: a qualitative analysis of the opinions of parents. [Poster Presentation], All-Ireland Schools of Pharmacy Conference, UCC . [Details] | |
| (2016) | AAPS/PSJ Joint Symposium: More Than Skin Deep: Using Microstructural Delivery Technology To Breach Skin Barrier, Anne Moore (2016) Microneedle Patches for Vaccine Stabilization and Enhanced Immunization”. [Invited Lectures (Conference)], AAPS/PSJ Joint Symposium: More Than Skin Deep: Using Microstructural Delivery Technology To Breach Skin Barrier, Denver CO, USA . [Details] | |
| (2016) | Irish Society for Immunology, J. McCaffrey, C. Bernelin, N. Bertho, I. Schwartz, V. Jakob, C. Barnier, D. McDaid, A. Moore (2016) Development of the dissolving microneedle platform for delivery of veterinary vaccines. [Invited Lectures (Conference)], Irish Society for Immunology, Cork . [Details] | |
| (2014) | Vaccines2014, Anne Moore (2014) Probing the effect of skin-based immunization using Pseudotyped virus-based assays. [Invited Oral Presentation], Vaccines2014, O2 London UK , 20-OCT-14 - 22-OCT-14. [Details] | |
| (2014) | The Modes of Action of Vaccine Adjuvants, O. Flynn, E. Allen, K. Dillane, A. Crean , E. Norton and A. Moore (2014) Immunogenicity of dmLT Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle. [Oral Presentation], The Modes of Action of Vaccine Adjuvants, Seattle, WA, USA , 08-OCT-14 - 13-OCT-14. [Details] | |
| (2014) | Third International Conference on Microneedles, Anne Moore (2014) Development of ImmuPatch Microneedle Systems for Immunization Programs. [Invited Oral Presentation], Third International Conference on Microneedles, Baltimore, MD, USA . [Details] | |
| (2014) | Third International Conference on Microneedles, E. Allen, O. Flynn, K. Dillane, C. O’Mahony, A. Crean and A. Moore (2014) Immunogenicity and Stability of Trivalent Inactivated Influenza Virus Vaccine in ImmuPatch Dissolvable Microneedles. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD, USA , 19-MAY-14 - 21-MAY-14. [Details] | |
| (2013) | “The pig as model in human vaccine development, Anne Moore (2013) Pig as a model for intradermal vaccination. [Invited Lectures (Workshops)], “The pig as model in human vaccine development, Central Veterinary Institute in Lelystad, NL , 20-SEP-03. [Details] | |
| (2013) | The pig as model in human vaccine development, Anne Moore (2013) Pig as a model for intradermal vaccination. [Invited Oral Presentation], The pig as model in human vaccine development, Leylstad, NL . [Details] | |
| (2013) | Irish Medical Device Association (IMDA) and Enterprise Ireland hosted “R&D Funding Opportunities through Horizon 2020, Anne Moore (2013) ImmuPatch. [Invited Oral Presentation], Irish Medical Device Association (IMDA) and Enterprise Ireland hosted “R&D Funding Opportunities through Horizon 2020, Galway . [Details] | |
| (2012) | Second International Conference on Microneedles, Anne Moore (2012) Co-Chair of Conference. [Conference Organising Committee Chairperson], Second International Conference on Microneedles, Cork, Ireland . [Details] | |
| (2012) | Sharebiotech: Fostering Open Innovation in Biotechnology, Crean, A.M., Moore A.C., O'Mahony C. (2012) ImmuPatch: a skin-deep approach to vaccination and drug delivery. [Invited Oral Presentation], Sharebiotech: Fostering Open Innovation in Biotechnology, Pamplona , 10-MAY-12 - 11-MAY-12. [Details] | |
| (2011) | Skin Vaccine Summit, Anne Moore; (2011) Development of Silicon and Dissolvable ImmuPatch Microneedle Devices for Vaccination. [Oral Presentation], Skin Vaccine Summit, Washington DC , 12-OCT-11 - 14-OCT-11. [Details] | |
| (2011) | PharmSciFair, A Moore; (2011) Development of Silicon and Dissolvable ImmuPatch Microneedle Devices for Vaccination. [Invited Oral Presentation], PharmSciFair, Prague , 11-OCT-11 - 14-OCT-11. [Details] | |
| (2011) | Insights into Successful Translational Research, Anne Moore (2011) SFI/HRB/MMI organised event. [Invited Oral Presentation], Insights into Successful Translational Research, Dublin . [Details] | |
| (2011) | Insights into Successful Translational Research, Anne Moore (2011) SFI/HRB/MMI organised national meeting. [Invited Seminars/Guest Lectures], Insights into Successful Translational Research, Dublin , 29-NOV-11. [Details] | |
| (2010) | First International Conference on Microneedles, Pearson F.E., Reyes-Sandoval A.,. O'Mahony C, Moore A.C., Hill A.V.S, ; (2010) Delivery of Recombinant Adenoviral Vector Malaria Vaccines by ImmuPatch Induces Protective CD8+ T Cell Mediated Immunity Against Parasite Challenge. [Poster Presentation], First International Conference on Microneedles, Atlanta, Georgia, , 24-MAY-10 - 26-MAY-10. [Details] | |
| (2010) | Perspectives in Percutaneous Penetreation, O'Mahony C, Blake A., Scully J., O'Brien J. and Moore A.C; (2010) Silicon Microneedles for Painless Percutaneous Penetration. [Poster Presentation], Perspectives in Percutaneous Penetreation, La Grande Motte, France , 06-APR-10 - 10-APR-10. [Details] | |
| (2009) | Modern Vaccines adjuvants and Delivery Systems, Carey J.B., Gilbert S.C., Vrdoljak, A., Hill A.V.S and Moore A.C; (2009) T cell inducing flu vaccines; Protective Efficacy and Strain Specificity. [Poster Presentation], Modern Vaccines adjuvants and Delivery Systems, Vienna, Austria , 28-OCT-09 - 30-OCT-09. [Details] | |
| (2009) | European Congress of Immunology, Carey J.B., Gilbert S.C., A., Hill A.V.S and Moore A.C. ; (2009) Immunogenicity and protective efficacy of a viral vectored candidate human pandemic influenza vaccine. [Oral Presentation], European Congress of Immunology, European Congress of Immunology, Berlin, Germany, , 13-SEP-09 - 16-SEP-09. [Details] | |
| (2009) | 2nd Annual Oxford Avian Influenza Conference, BirdFlu2009, Carey J.B., Gilbert S.C., A., Hill A.V.S and Moore A.C ; (2009) Pre-clinical assessment of a candidate T cell inducing viral vectored vaccine for human influenza viru. [Oral Presentation], 2nd Annual Oxford Avian Influenza Conference, BirdFlu2009, Oxford, UK , 10-SEP-09 - 11-SEP-09. [Details] | |
| (2007) | Unknown, Moore, A. C. ; (2007) Anti-CD25 Antibody Enhancement of Vaccine-induced immunogenicity; translation form Mouse to Primates. [Oral Presentation], Unknown, Cork, Ireland , 01-JUN-07 - 01-JUN-07. [Details] | |
| (2007) | Vaccine Induced Immunity to Fight Disease, Moore, A. C. ; (2007) unknown. [Oral Presentation], Vaccine Induced Immunity to Fight Disease, Biochemistry Dept., UCC, , 01-APR-07 - 01-APR-07. [Details] | |
| (2009) | Big Ideas Showcase 2009, Moore, A. C.,Carey, J. B..,Vrdoljak, A.,McGrath, M. G.,Crean, A.,O'Mahony, C. (2009) ImmuPatch: Innovative Solutions to Vaccine Delivery Barriers. [Oral Presentation], Big Ideas Showcase 2009, Dublin, Ireland . [Details] | |
| (2007) | T cell Inducing Influenza Virus Vaccines, Moore A.C., Gallimore A., Draper S., Watkins K.R., Gilbert S.C. and Hill A.V.S. ; (2007) unknown. [Oral Presentation], T cell Inducing Influenza Virus Vaccines, University of Johannesburg , 01-OCT-07 - 01-OCT-07. [Details] | |
| (2006) | Malaria and TB Vaccines; Modulating, Protective and Regulatory T cell responses, Moore, A. C. ; (2006) Control of anti-tumoral and anti-infectious immune responses by Regulatory T cell subsets: potential clinical applications. [Oral Presentation], Malaria and TB Vaccines; Modulating, Protective and Regulatory T cell responses, Annecy, France , 01-SEP-06 - 01-SEP-06. [Details] | |
| (2005) | Virus Vector Based Vaccines, Moore, A. C. ; (2005) unknown. [Oral Presentation], Virus Vector Based Vaccines, University of Nottingham , 01-APR-05 - 01-APR-05. [Details] | |
| (2005) | Assaying Potency of Novel Vaccines, Moore, A. C. ; (2005) Potency of Poxviral Based Vectors for Malaria and TB vaccines. [Oral Presentation], Assaying Potency of Novel Vaccines, NIH, Bethesda, MD , 01-OCT-05 - 01-OCT-05. [Details] | |
| (2005) | Tropical Network Meeting, Moore, A. C. ; (2005) Improving Immunogenicity by Deregulating Malaria Vaccines. [Oral Presentation], Tropical Network Meeting, Kilifi, Kenya , 01-SEP-05 - 01-SEP-05. [Details] | |
| (2005) | British Council, INYS meeting, Moore, A. C. ; (2005) Progress in Virus Vector based Malaria and TB vaccines. [Oral Presentation], British Council, INYS meeting, Dunedin, New Zealand , 01-MAR-05 - 01-MAR-05. [Details] | |
| (2004) | Keystone Symposium: Rational Design of Vaccines and Immunotherapeutics, Moore, A. C. ; (2004) PRE-EXISTING FOWLPOX IMMUNITY IS LESS INHIBITORY TO HETEROLOGOUS PRIME-BOOST VACCINE STRATEGIES COMPARED TO ANTI-MVA IMMUNITY. [Oral Presentation], Keystone Symposium: Rational Design of Vaccines and Immunotherapeutics, Keystone Resort, Keystone, Colorado , 01-MAR-04 - 01-MAR-04. [Details] | |
| (2004) | University of Wales College of Medicine BSI seminar series, Moore, A. C. ; (2004) Prime Boost Malaria Vaccines. [Oral Presentation], University of Wales College of Medicine BSI seminar series, Wales , 01-DEC-04 - 01-DEC-04. [Details] | |
| (2004) | British Society for Immunology, Moore, A. C. ; (2004) Progress in Malaria and TB vaccines; improved de-regulated vaccine strategies. [Oral Presentation], British Society for Immunology, Harrogate, UK , 01-DEC-04 - 01-DEC-04. [Details] | |
| (2014) | Third International Conference on Microneedles, Baltimore, O. Flynn, E. Allen, K. Dillane, A. Quinlan, C. O’Mahony, A. Crean, E. Norton and A. Moore (2014) Immunogenicity of Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle Patches in Mice. [Poster Presentation], Third International Conference on Microneedles, Baltimore, Baltimore, MD, USA , 19-MAY-14 - 21-MAY-14. [Details] | |
| (2014) | Third International Conference on Microneedles, K. Dillane, T. Aherne, A. Offroy, C. O’Mahony, A. Crean and A. Moore (2014) Assessment of the physical stability of trehalose dissolvable microneedles in an ambient temperature and humidity environment. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD , 19-MAY-14 - 21-MAY-14. [Details] | |
| (2014) | Third International Conference on Microneedles, Sonja Vucen, Gordana Vuleta, Jela Milic, Abina Crean, Anne Moore, Nenad Ignjatovic, Dragan Uskokovic (2014) Short-term storage stability of dissolvable microneedles containing ketoprofen-loaded polymeric nanoparticles. [Oral Presentation], Third International Conference on Microneedles, Baltimore, MD, USA , 19-MAY-14 - 21-MAY-14. [Details] | |
| (2014) | Third International Conference on Microneedles, C. O’Sullivan, M.A.P. McAuliffe, E. O’Neill, A. Moore, A. Crean (2014) Raman Spectroscopy as a Qualitative Tool to Characterise Solid State Properties of Drug-Loaded Dissolvable Microneedles. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD, USA , 19-MAY-04 - 21-MAY-14. [Details] |
Professional Associations
| Association | Function | From / To | |
|---|---|---|---|
| Burroughs-Wellcome sponsored; "Malaria Liver-stage Genomics and Proteomics", Washington DC | Contributor | / | |
| "The use of non-human primates in research", chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society | Consultee to the working group | / | |
| Livestock Vaccine Enterprise Initiative Meeting, Wellcome Trust Centre for Human Genetics | Invited delegate to initiate international veterinary vaccine consortium | 17-MAY-07 / 18-MAY-07 | |
| New Trends in Cancer Immunotherapy. Fondation Merieux | Invited Participant | 08-JUL-07 / 11-JUL-07 |
Employment
| Employer | Position | From / To | |
|---|---|---|---|
| University College Cork | Lecturer | 01-JAN-07 / | |
| University of Oxford | Senior Immunologist | 01-JAN-02 / 01-JAN-06 | |
| University of Oxford | Postdoctoral Associate | 01-JAN-01 / 01-JAN-02 | |
| University of Michigan | Postdoctoral Associate | 01-JAN-98 / 01-JAN-01 | |
| The Wistar Institute, Philadelphia, USA | Postdoctoral Scientist | 01-SEP-97 / 31-JUL-98 |
Outreach Activities
| Description | |
|---|---|
Erasmus Co-ordinator, School of Pharmacy (Dec 2007-present). | |
http://www.irishexaminer.com/viewpoints/analysis/cracking-the-vaccine-conundrum-307481.html | |
Developing women leaders in higher education. Identity, Imapct and Voice Session Thursday 7 January 2016. Dublin | |
Online event where school students meet and interact with scientists. It’s an X Factor-style competition between scientists, where the students are the judges. August 2015. | |
Pioneering science in Ireland: students can follow in their footsteps. Irish Times 26th May 2015. http://www.irishtimes.com/news/education/pioneering-science-in-ireland-students-can-follow-in-their-footsteps-1.2221296 | |
Technology Ireland Newsletter Nov 2009 | |
New technology to help combat malaria developed at UCC. Microneedle based patch said to require lower levels of vaccine to be effective. Irish Times Sep 3, 2014 http://www.irishtimes.com/news/ireland/irish-news/new-technology-to-help-combat-malaria-developed-at-ucc-1.1916744 | |
UCC’s ‘malaria patch’ en route to Silicon Valley. Irish Examiner September 04, 2014 http://www.irishexaminer.com/ireland/uccs-malaria-patch-en-route-to-silicon-valley-284797.html |
Journal Activities
| Journal | Role | To / From | |
|---|---|---|---|
| Frontiers In Immunology | Member of Editorial Board | 01-MAR-22 - | |
| Vaccines | Member of Editorial Board | 01-DEC-21 - | |
| Plos One | Member of Editorial Board | 01-MAY-14 - | |
| Scientific Reports | Member of Editorial Board | 01-DEC-15 - 15-DEC-17 | |
| Vaccine | Referee | - | |
| Expert Review Of Vaccines | Referee | - | |
| Immunological Reviews | Referee | - | |
| Journal Of Controlled Release : Official Journal Of The Controlled Release Society | Referee | - |
Research Information
Internal Collaborators
| Name | Institute | Country | |
|---|---|---|---|
| Dr. Laura Sahm | School of Pharmacy | IRELAND | |
| Dr. Abina Crean | UCC | IRELAND | |
| Dr. Aoife Fleming | UCC | IRELAND |
External Collaborators
| Name | Organisation / Institute | Country | |
|---|---|---|---|
| Dr. Sean Tucker | Vaxart | U.S.A. | |
| Dr. Norbert Stockhofe | Wageningen University | HOLLAND | |
| Prof. Joke Bouwstra | University of Leiden | HOLLAND | |
| Dr. Isabelle Schwartz-Corneil | INRA | FRANCE | |
| Prof. Simon Draper | University of Oxford | UNITED KINGDOM |